BRIEF—Mitsubishi and Janssen tweak Stelara collaboration in Japan

Mitsubishi Tanabe Pharma and Janssen Pharmaceutical, the pharmaceutical division of Johnson & Johnson, have altered the terms of their Japanese collaboration around Stelara (ustekinumab).

Distribution will now be transferred to Mitsubishi Tanabe, while the two firms will continue co-promotion for Crohn’s disease in Japan. For the indication of psoriasis, promotion will be handled solely by Janssen.

The firms will also continue to co-promote Simponi (golimumab) to treat patients living with moderate to severe rheumatoid arthritis or ulcerative colitis in Japan.